We use cookies to help us improve your browsing experience and understand how people use our website. Our privacy statement explains how we use cookies, and how to change your cookie settings.

Take a look at our previous reports:

Annual Report

2018

View Report

Q1 Report

2019

View Report

H1 Report

2019

View Report

Q3 Report

2019

View Report
English | Dutch
Jump to content [AK + s] Jump to navigation [AK + 3]

Annual Report 2019

  • Twitter
  • LinkedIn

Primary Menu

  • The Galapagos group
    • Letter from the management
    • At a glance
    • Strategy
    • Going concern statement
    • Risk management and internal control
    • The Galapagos share
    • Overview of Galapagos NV
    • Disclaimer and other information
  • R&D
    • Our pipeline and drug discovery engine
    • Target discovery platform
    • Filgotinib in inflammation
      • Filgotinib in RA
      • Filgotinib in IBD
      • Filgotinib in psoriatic arthritis
      • Other indications with filgotinib
    • Our fibrosis portfolio
      • About IPF
      • Our IPF trials
      • Our fibrosis trials
    • Our OA program
    • Our Toledo program
    • Early, deep pipeline
    • Other partnered programs
  • Risk factors
    • Product development, regulatory approval and commercialization
    • Financial position and need for additional capital
    • Reliance on third parties
    • Competitive position
    • Intellectual property
    • Organization, structure and operation
    • Galapagos shares
    • General statement
  • CSR report
    • Our commitment
    • Improving people’s lives
    • Our employees
    • Conducting business ethically
    • Environment, health, and safety
    • CSR at Galapagos – Summary
  • Corporate governance
    • Policies
    • Board of directors
    • Committees
    • Share capital and shares
    • Shareholders
    • Remuneration policy
      • Determination of remuneration
      • Remuneration policy for directors
      • Remuneration policy for executive committee members
      • Deviations from this policy
    • Remuneration report
      • Non-executive directors
      • Executive directors
      • Criteria and methods to evaluate performance
      • Gross remuneration of CEO
      • Gross remuneration of other executive committee members
      • Warrants awarded to executive committee members
      • RSUs awarded to executive committee members
      • Provisions for severance
      • Severance payments in 2019
      • Claw-back right
    • Conflict of interests and related parties
    • Code of Business Conduct and Ethics
    • Statement by the board of directors
  • Financial statements
    • Consolidated financial statements
      • Statements of income and comprehensive income/loss (-)
      • Statements of financial position
      • Cash flow statements
      • Statements of changes in equity
    • Notes to the consolidated financial statements
      • Notes 1-10
        • 1. General information
        • 2. Summary of significant transaction
        • 3. Significant accounting policies
        • 4. Critical accounting judgments and key sources of estimation uncertainty
        • 5. Segment information
        • 6. Total revenues and other income
        • 7. Operating costs
        • 8. Staff costs
        • 9. Fair value re-measurement of share subscription agreement and warrants granted to Gilead
        • 10. Other financial income/expenses
      • Notes 11-20
        • 11. Income taxes
        • 12. Income/loss per share
        • 13. Intangible assets
        • 14. Property, plant and equipment
        • 15. Other non-current assets
        • 16. Research and development incentives receivables
        • 17. Trade and other receivables and other current assets
        • 18. Current financial investments
        • 19. Cash and cash equivalents
        • 20. Share capital
      • Notes 21-30
        • 21. Deferred tax
        • 22. Lease liabilities
        • 23. Trade and other liabilities
        • 24. Deferred income
        • 25. Note to the cash flow statement
        • 26. Off-balance sheet arrangements
        • 27. Contingent assets and liabilities
        • 28. Warrant plans
        • 29. Related parties
        • 30. Consolidated companies as of 31 December 2019
      • Notes 31-33
        • 31. Financial risk management
        • 32. Statutory auditor’s remuneration
        • 33. Events after balance sheet date
    • Non-consolidated financial statements
  • Auditor's report
    • Report of the statutory auditor
  • Magazine
Downloads

Financial statements

  • Consolidated financial statements
    • Statements of income and comprehensive income/loss (-)
    • Statements of financial position
    • Cash flow statements
    • Statements of changes in equity
  • Notes to the consolidated financial statements
    • Notes 1-10
      • 1. General information
      • 2. Summary of significant transaction
      • 3. Significant accounting policies
      • 4. Critical accounting judgments and key sources of estimation uncertainty
      • 5. Segment information
      • 6. Total revenues and other income
      • 7. Operating costs
      • 8. Staff costs
      • 9. Fair value re-measurement of share subscription agreement and warrants granted to Gilead
      • 10. Other financial income/expenses
    • Notes 11-20
      • 11. Income taxes
      • 12. Income/loss per share
      • 13. Intangible assets
      • 14. Property, plant and equipment
      • 15. Other non-current assets
      • 16. Research and development incentives receivables
      • 17. Trade and other receivables and other current assets
      • 18. Current financial investments
      • 19. Cash and cash equivalents
      • 20. Share capital
    • Notes 21-30
      • 21. Deferred tax
      • 22. Lease liabilities
      • 23. Trade and other liabilities
      • 24. Deferred income
      • 25. Note to the cash flow statement
      • 26. Off-balance sheet arrangements
      • 27. Contingent assets and liabilities
      • 28. Warrant plans
      • 29. Related parties
      • 30. Consolidated companies as of 31 December 2019
    • Notes 31-33
      • 31. Financial risk management
      • 32. Statutory auditor’s remuneration
      • 33. Events after balance sheet date
  • Non-consolidated financial statements

You are here:

  • Home
  • Financial statementsNotes to the consolidated financial statements
  • Notes 21-30

Notes 21-30

Notes to the consolidated financial statements
 CSR report
Galapagos NV • Annual Report 2019
  • 21. Deferred tax
  • 22. Lease liabilities
  • 23. Trade and other liabilities
  • 24. Deferred income
  • 25. Note to the cash flow statement
  • 26. Off-balance sheet arrangements
  • 27. Contingent assets and liabilities
  • 28. Warrant plans
  • 29. Related parties
  • 30. Consolidated companies as of 31 December 2019
  • Downloads
  • Financial calendar
  • Glossary of terms
previous pagenext page

Magazine Pioneering for patients

Discover more about our historic year

Galapagos Annual Report 2019 (PDF)

(PDF:) Download PDF (4.8 MB)
English | Dutch
  • © Copyright 2020 Galapagos NV
  • Colophon
  • Contact
  • Privacy notice
  • Downloads
  • Glossary of terms

© Copyright 2020 Galapagos NV

nexxar - digital reporting evolved - Online Report